{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"EINE\nPROSPEKTIVE, RANDOMISIERTE, OFFENE PHASE-II-STUDIE ZUR BEURTEILUNG DER\nÜBERLEGENHEIT EINER MONOTHERAPIE MIT INOTUZUMAB OZOGAMICIN IM VERGLEICH ZUR\nALLR3 INDUKTIONSTHERAPIE DES PÄDIATRISCHEN HOCHRISIKO-ERSTREZIDIVS DER AKUTEN\nLYMPHATISCHEN LEUKÄMIE VOM B-VORLÄUFER-TYP","eudractNumber":"2022-000186-40","id":8458,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"Others","id":"mt_8"}],"nctNumber":"NCT05748171","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-07-28T09:37:30+02:00","shortTitle":"B1931036","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Encorafenib Plus Binimetinib in Patients With Locally Advanced, \nUnresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, \nMultinational, Prospective, Longitudinal, Non-interventional Study in \nGermany, Austria and Switzerland","eudractNumber":null,"id":5940,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"}],"nctNumber":"NCT04045691","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2019-10-31T08:21:58+01:00","shortTitle":"BERING MELANOMA","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/ Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma and t(11; 14)","eudractNumber":"2021-003614-39","id":9079,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"Translokation","id":"mt_244"},{"name":"t(11;14)","id":"mt_78"}],"nctNumber":"NCT04973605","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2025-05-07T12:24:50+02:00","shortTitle":"BGB-11417-105","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"

A First – in Human\nPhase I, non-randomized, open-label, multicenter dose escalation trial of BI\n764532 administered by repeated intravenous infusions in patients with Small\nCell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

","eudractNumber":"2019-000729-31","id":6385,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[{"name":"DLL3 (Delta-like 3)","id":"mt_29"}],"nctNumber":"NCT04429087","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2021-10-14T14:19:12+02:00","shortTitle":"BI 1438-0001","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"
A Phase I study to determine the safety and tolerability of BI 3820768 in patient.s with advanced relapsed or refractory germ cell tumours, endometrial cancer, or ovarian cancer
","eudractNumber":"2025-522913-45-00","id":11551,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro3","name":"Hodenkarzinom"}],"mutations":[],"nctNumber":"NCT07306559","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2026-06-16T09:36:01+02:00","shortTitle":"BI 2001-0001","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"

A Phase 1/2 Study of BMS-986340 as Monotherapy and in\nCombination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors 

EUDRA-CT Nummer geändert 18.12.2023

von 2021-001188-26 auf  2023-503651-10-00

","eudractNumber":"2023-503651-10","id":7045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[],"nctNumber":"NCT04895709 ","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-07-14T10:18:54+02:00","shortTitle":"BMS CA052-002","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide \n(CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and \nDexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): \nSUCCESSOR-2","eudractNumber":"2022-500861-29","id":10516,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05552976","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-11T10:53:21+02:00","shortTitle":"BMS CA057-008 - SUCCESSOR-2","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
","eudractNumber":"2024-517422-25","id":11018,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-23T09:38:08+02:00","shortTitle":"BMS CA071-1000","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma
(GOLSEEK-4)
","eudractNumber":"2024-519152-82","id":11182,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06911502","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-24T13:25:31+02:00","shortTitle":"BMS CA0731003 GOLSEEK-4","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3, Randomized, Open-Label, Multicenter Study to 'Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)","eudractNumber":"2022-501346-30-00","id":9854,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06615479","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-01T09:47:06+02:00","shortTitle":"BMS CA088-1007","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]}]},"initialUrl":"/api/studies?lang=de&page=3&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"EINE\\nPROSPEKTIVE, RANDOMISIERTE, OFFENE PHASE-II-STUDIE ZUR BEURTEILUNG DER\\nÜBERLEGENHEIT EINER MONOTHERAPIE MIT INOTUZUMAB OZOGAMICIN IM VERGLEICH ZUR\\nALLR3 INDUKTIONSTHERAPIE DES PÄDIATRISCHEN HOCHRISIKO-ERSTREZIDIVS DER AKUTEN\\nLYMPHATISCHEN LEUKÄMIE VOM B-VORLÄUFER-TYP\",\"name\":\"B1931036\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8458\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Encorafenib Plus Binimetinib in Patients With Locally Advanced, \\nUnresectable or Metastatic BRAFV600-mutated Melanoma: a Multi-centric, \\nMultinational, Prospective, Longitudinal, Non-interventional Study in \\nGermany, Austria and Switzerland\",\"name\":\"BERING MELANOMA\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/5940\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone and Carfilzomib/ Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma and t(11; 14)\",\"name\":\"BGB-11417-105\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9079\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

A First – in Human\\nPhase I, non-randomized, open-label, multicenter dose escalation trial of BI\\n764532 administered by repeated intravenous infusions in patients with Small\\nCell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

\",\"name\":\"BI 1438-0001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/6385\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
A Phase I study to determine the safety and tolerability of BI 3820768 in patient.s with advanced relapsed or refractory germ cell tumours, endometrial cancer, or ovarian cancer
\",\"name\":\"BI 2001-0001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11551\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

A Phase 1/2 Study of BMS-986340 as Monotherapy and in\\nCombination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors 

EUDRA-CT Nummer geändert 18.12.2023

von 2021-001188-26 auf  2023-503651-10-00

\",\"name\":\"BMS CA052-002\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7045\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide \\n(CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and \\nDexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): \\nSUCCESSOR-2\",\"name\":\"BMS CA057-008 - SUCCESSOR-2\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10516\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
\",\"name\":\"BMS CA071-1000\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11018\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma
(GOLSEEK-4)
\",\"name\":\"BMS CA0731003 GOLSEEK-4\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11182\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 3, Randomized, Open-Label, Multicenter Study to 'Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)\",\"name\":\"BMS CA088-1007\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9854\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=4\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}